The net loss is still reported despite lessening of expenses.
Aslan Pharmaceuticals reported a net loss of $3.5m for the third quarter of 2020 but still less than last year’s $5.2m net loss in the same time period.
Cash expenditure for operations for Q3 was $2.6m, less than the $7m in the same period in 2019.
The company also reported that expenses for research and development were less in Q3 compared to last year because of the completion of clinical studies related to varlitinib.
Do you know more about this story? Contact us anonymously through this link.